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Summary  
We used polyclonal antisera nd monodonal ntibodies (mAbs) to inhibit the growth of clonal 
populations of two strains of Borrelia burgdorferi, the Lyme disease agent, and thereby select for 
antibody-resistant mutants, mAbs were directed at the outer membrane proteins, OspA or OspB. 
Mutants resistant o the growth-inhibiting properties of the antibodies were present in the 
populations at frequencies ranging from 10 -s to 10 -2. The several escape variants that were 
examined were of four classes. Class I mutants were resistant o all mAbs; they lacked OspA 
and OspB and the linear plasmid that encodes them. Two other proteins were expressed in larger 
amounts in class I mutants; mAbs to these proteins inhibited the mutant but not the wild-type 
cells. Class II mutants were resistant to some but riot all mAbs; they had truncated OspA and/or 
OspB proteins. Class III mutants were resistant only to the selecting mAb; they had full-length 
Osp proteins that were not bound by the selecting antibody in Western blots. In two class III 
mutants resistant o different anti-OspA mAbs, missense mutations were demonstrated in the 
ospA genes. Class IV mutants were likewise resistant only to selecting antibody, but in this case 
the selecting antibody still bound in Western blots. 
I n vitro selection of antigenic variants or mutants with an- tibodies has proven a valuable strategy for identifying or 
further characterizing antigens of infectious agents. Several 
different viruses have been studied by this approach: poliovirus 
(1), cytomegalovirus (2), coxsackie B (3), hepatitis A (4), hep- 
atitis B (5), visna (6), rabies (7), Herpes implex (8), influenza 
A (9, 10), and Newcastle disease (11) viruses among others. 
In vitro selection of antibody escape variants has also been 
successfully carried out from populations ofparasites including 
Plasmodium chabaudi (12), P. berghei (13), and Trypanosoma equi- 
perdum (14) in recent years. 
Although in vitro selection of variants with antibodies was 
first demonstrated with bacteria (reviewed by Hadley in 1926 
in reference 15), this experimental approach as seldom been 
applied to pathogenic bacteria since the 1950's. This is ironic 
in the heyday of molecular microbiology, because several of 
these arly studies were directly or indirectly concerned with 
the bacterium's hereditary material. Dawson's finding in 1928 
(16) that "S" forms of pneumococci could be selected from 
clonal populations of "R" forms by adding anti-"R" serum 
to the broth medium was one of the steps toward the eluci- 
dation of the identity of the transforming substance inpneu- 
mococci as DNA. Leidy et al. (17) used in vitro selection 
in their studies of transformation f Hemophihs influenzae 
in 1953. A year later, Uetake et al. (18) demonstrated that 
antisera in the growth medium selected for alternate flagella 
in the biphasic variation of Salmonella. In recent decades the 
only consistent application of this approach for bacteria has 
been the studies of antigenic variants ofLeptost, ira interrogans 
by Shimono and Yanagawa (19), and in these studies the genetic 
basis for the escape mutations had not been determined. 
Notwithstanding infrequent application for bacterial studies 
presently, there were compelling reasons to use in vitro anti- 
body selection with Borrelia burgdorferi, the agent of Lyme 
disease. First, we had shown for the related species,/t hermsii, 
that an antiserum specific for one serotype could select for 
new serotypes in an isogenic population undergoing invitro 
growth (20). The ability of polyclonal antisera nd mAbs 
to agglutinate (21) and inhibit the growth of/g burgdorferi 
(21a) indicated that this was also possible with the Lyme dis- 
ease agent. Second, previous tudies had shown antigenic differ- 
ences in outer membrane proteins, OspA and OspB, between 
strains (21-26) and also true antigenic variation of these pro- 
teins within a strain (25, 27-30). If borrelias did "escape" 
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killing (31), growth inhibition (32), or agglutination (21) 
by antibodies, it was likely that this was the consequence of
antigenic variation. Third, the success of passive immuniza- 
tion with either polyclonal antisera or mAbs in protecting 
animals indicated that an in vitro study of antibody effects 
was relevant for studies of pathogenesis and immunopro- 
phylaxis of Lyme disease (33-38). 
In the present study we demonstrate in vitro sdection of 
antibody-resistant mutants o fR  burgdorferi. Among the sev- 
eral escape mutants evaluated, four major phenotypic classes 
were identified, and for two classes genotypes were determined. 
Materials and Methods 
Strains and Culture Conditions. 17, burgdorferi isolates were the 
following: B31 (35210; American Type Culture Collection, Rock- 
viUe, MD) (39) and HB19, a human blood isolate (30, 40). Cul- 
tures of strains B31 and HB19 had been passed continuously from 
1982 and 1983, respectively, and each had been cloned at least wice 
by limiting dilution or colony plating (30). For some of the experi- 
ments these strains were cloned again by colony plating. Borrelias 
were grown in broth BSK II medium and harvested by methods 
previously described (41, 42). Cells were counted in a Petroff-Hauser 
chamber by phase-contrast microscopy. In some experiments bor- 
relias were also grown as isolated in solid medium (42a). In brief, 
borrelias were added to BSK II medium with 1% low-geUing tem- 
perature agarose (SeaPlaque; FMC Corporation, Rockland, ME) 
kept liquid at 37~ The cell suspension was then poured as a thin 
layer over solid BSK II medium containing 1.5% agarose in small 
polystyrene petri dishes (30). The plates were incubated at 34~ 
in a candle jar for 7-10 d, by which time colonies were visible to 
the naked eye. 
Antibodies. The origins of the OspA-specifir mAb H5332 
(IgG2A; 42) and H3TS (IgG3; 22); the OspB-specific mAbs H6831 
(IgG2A; 21), H614 (IgG3; 30), and H68 (IgG2A; 30); the VmpC- 
specific mAb H4825 (IgG2A; 21); and the Vmp21-specific mAb 
H10022 (IgG3; 43) have been given. In previous tudies the fol- 
lowing Western blot results were obtained: H5332, H3TS, H614, 
and H68 bound to B31 and HB19 (22, 30, 42, and our unpublished 
data); H6831 bound to B31 but not HB19 (21); and H4825 only 
bound to BhC (21). H10022 bound onty to serotype 21 cells of 
1~ hermsii strain HSl (43). The OspA-specific mAb 6A4B (IgG2b) 
was the gift of Denee Thomas (University of Texas) (Comstock 
et al., manuscript submitted for publication). Specificities and reac- 
tivities of mAbs were confirmed by indirect immunofluorescence 
assay as previously described (42). 
Additional mAbs were produced for this study. Adult female 
BALB/c mice were inoculated intraperitoneally on days 1 and 21 
with 2 x 10 s viable borrelias in PBS. On day 53, the mice were 
injected intravenously with 0.5 x 10 s viable borrelias in PBS. Fu- 
sion of the mouse spleen cells with NS1 myeloma cells were per- 
formed on day 57 by a modification of the method of Oi and Her- 
zenberg (44). Hybridoma supematant fluids were screened by ELISA 
(45, 46) and then by Western blot analysis (see below). Hybrid- 
omas were cloned by limiting dilution, and ascites from the hy- 
bridomas were produced as described previously (47). The isotypes 
of antibodies were determined using a commercial kit (Immuno- 
type; Sigma Chemical Co., St. Louis, MO). 
6-8-wk-old female Lewis rats (LEW/N; Harlan-Sprague-Dawley, 
Indianapolis, IN) were immunized with viable HIB19 cells sus- 
pended in PBS as described previously (21a). In brief, for the first 
immunization the cell suspension was emulsified with CFA, and 
for the booster immunization at4 wk the suspension i PBS alone 
was used. Serum was obtained uring weeks 5 and 6 and pooled. 
Mutant Selection i Broth and Solid Media. Conditions for growth 
inhibition with polyclonal antisera or mAbs in sealed, 96-we11, flat- 
bottomed microtiter plates were essentially as described (21a). The 
initial inocuh of spirochetes ineach well varied by experiment. The 
antisera nd ascitic fluids did not contain preservatives or antibi- 
otics, and were heat-inactivated (56~ for 30 rain) and filter steri- 
lized before use. In general, the dilution of antisera nd ascitic fluids 
used for selection were at least twice the minimal concentrations 
required for growth inhibition (21a). A previous tudy had shown 
that the growth medium did not contain rabbit complement 
sufficient o detectably enhance growth inhibition by antibody. 
Growth at 34~ in a 1% COz atmosphere was monitored visually 
for changes in the color of the phenol red indicator and by phase 
contrast microscopy of wet-mounts of culture samples. In some 
experiments selection was carried out in tightly capped, 13 x 100- 
mm polystyrene culture tubes (Falcon Labware, Lincoln Park, NJ) 
containing 6 ml medium. For selection of antibody-resistant mu- 
tants in solid medium, the antiserum or ascitic fluid was diluted 
1:100 in the top agarose at the time of the addition of the spirochetes. 
The bottom agarose did not contain antibody. Resistant colonies 
appeared on the plates within 7-10 d. Once cultures or colonies 
with antibody-resistant borrelias were identified, the populations 
were serially passed in medium first with and then without the 
selecting antibody. Variants were cloned by limiting dihtion or 
single-colony plating (30). 
In Situ Protease Treatment. Cleavage of surface-exposed proteins 
of viable borrelias with proteinase K (Boehringer Mannheim, In- 
dianapolis, IN) was a modification of a previously described method 
(21). A 10-#1 volume of an aqueous olution of proteinase K (20 
mg/ml) was added to 490 #1 of a suspension containing 109 
washed borrelias/ml of PBS. After incubation of the cells with pro- 
tease for 40 rain at 22~ the reaction was stopped by addition 
of PMSF. To assess the specificity of the protease for surface acces- 
sible proteins, the motility of the spirochetes after protease treat- 
ment was observed by phase-contrast microscopy. Under the con- 
ditions described here, >95% of the spirochetes were motile after 
protease xposure. 
PAGE and Western Blot Analysis. Whole-cell ysates were sub- 
jected to PAGE with 12.5% acrylamide as previously described (42, 
47). For Western blot analysis, proteins were transferred tonitrocel- 
lulose membranes, which were then blocked with 3% (wt/vol) 
dried, nonfat milk in 10 mM Tris-HCl, pH 7.4, 150 mM NaCI 
(milk/10 mm Tris-HC1-150 mm NaC1 ['IS]) for 2 h. After the mem- 
branes were washed with milk/TS, they were incubated with mAbs 
in ascitic fluid diluted 1:100 in milk/TS. After washing with 
milk/TS, the blots were incubated for 1 h with alkaline phospha- 
tase-conjugated, recombinant protein A/G (Immunopure; Pierce 
Chemical Co., Rockford, IL) diluted in milk/TS. The blots were 
developed using nitro blue tetrazolium chloride/5-bromo-4-chloro- 
Y-indolylphosphate p-toluidine salt (NBT/BCIP) (Pierce Chem- 
ical Co.). 
DNA Extraction and Southern Blot Analysis. Extractions of total 
DNA and plasmid-enriched DNA from the borrelias, standard 
agarose dectrophoresis, Southern blot analysis, and direct gel hy- 
bridization of low-percentage agarose gels were performed as de- 
scribed previously (22, 30, 48, 49). The probes for the ospA and 
ospB genes of HIB19 and B31 were recombinant plasmids pTRH43 
and pTRH46, respectively (50-52). The probe DNA was labded 
with ol-[32p]dATP by nick transhtion using a commercial kit 
(Bethesda Research Laboratories, Gaithersburg, MD). Hybridiza- 
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tion fluid contained 50% formamide; the blots were incubated with 
the probe at 37"C overnight. The blots were washed with 15 mM 
NaC1, 1.5 mM sodium citrate, 1mM EDTA, 0.1% SDS at 640C. 
DNA Sequencing. The ospAB loci of selected variants, which 
had been cloned by single colony plating, were amplified by PCR 
essentially asdescribed previously (53, 54) and directly sequenced 
using the dideoxy method and a dsDNA Cycle Sequencing kit
(Bethesda Research Laboratories). PCR primers rept,~sented nucleo- 
tides 1-20 and 1896-1915 (opposite strand) of the 0sp locus equence 
(52; GenBank accession number X14407). Approximately 100 ng 
of total borrelial DNA was amplified for 20 cycles with the fol- 
lowing conditions: 940C for 1 rain, 500C for 30 s, and 700C for 
3 min. Taq polymerase (Perkin-Elmer-Cetus, Norwalk, CT) was 
used and the buffer conditions were as recommended by the sup- 
plier. Before sequencing, PCR fragments were purified by precipi- 
tation in 2 M ammonium acetate with an equal volume of 
isopropanol. Sequencing primers were located approximately very 
200 nucleotides throughout the osp operon and were labeled by 
T4 kinase with 32p. Approximately 10ng amplified DNA was 
used per sequencing reaction, and cycle sequencing conditions were 
as follows: 20 cycles at 950C for 30 s, 550C for 30 s, and 70~ 
for 1 min. Nucleic acid sequences were deposited into the EMBL 
database. 
Results 
Selection of Antibody-resistant Mutants. During development 
of the in vitro growth inhibition assay (21a), we observed 
microscopically that, even when overall growth was clearly 
inhibited and the majority of spirochetes were aggregated, 
blebbed, and nonmotile, there were rare spirochetes in the 
antibody-treated cultures that remained isolated, smooth sur- 
faced, and motile. We reasoned that if the persisting, motile 
spirochetes were antigenic variants, upon subsequent passages 
into fresh, antibody-containing medium, the proportion of 
motile spirochetes would further increase. Alternatively, if
motile spirochetes were antibody bound but had yet to ag- 
gregate or cease movement, then we would expect hat the 
proportion of motile cells in the cultures would not increase 
during serial passage in the presence of the same antibody. 
To distinguish between these xplanations, we serially passed 
1?, burgdotferi isolates in medium containing antisera and mAbs. 
In our first experiments we used broth cultures containing 
a total inoculum of 10 s spirochetes and either at polyclonal 
serum or mAbs to OspA and OspB, such as H5332 and H614. 
After 3-7 d of incubation, we blindly transferred 0.1 ml to 
6 ml fresh medium containing the same antibody concentra- 
tion. This was repeated after another 3-7 d of incubation. 
At least hree different tubes were used for each selecting an- 
tibody. Control tubes either without antibody or with ir- 
relevant antibodies were passed in parallel. 
When the first cultures were compared with the second 
and third cultures, the proportion of motile cells in the tube 
increased from <1% in the first cultures to >90% in the third 
culture. After two to three passages, the cell counts at entry 
into stationary phase of "resistant" cultures in antibody- 
containing medium were as high as the wild-type strain grown 
in the absence of antibody or in the presence of irrelevant 
antibodies. The resistant phenotypes remained after cloning 
by limiting dilution or single-colony plating and through 
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at least 6-20 serial passages in the absence of selecting anti- 
body. After the demonstration with broth cultures of the 
sdection of resistant variants, we studied the selection 
phenomenon further using broth medium in microtiter plates 
and sdid medium as described below. 
Many resistant variants were obtained uring the course 
of the foregoing studies and have been stored for further anal- 
ysis. Full description of each of the variants and precise de- 
termination ofthe frequency of each type of mutation isbe- 
yond the scope of this report. Nevertheless, a survey of 
randomly selected variant populations from both broth and 
solid medium was carried out for this study. All of the vari- 
ants catalogued here had stable resistance phenotypes through 
serial passage in the absence of antibody and after cloning 
by either limiting broth dilution or colony plating. Each of 
these variants were subjected to PAGE and Western blot anal- 
yses; some were further characterized by in situ treatment 
with protease, Southern blot analysis, and DNA sequencing. 
Although it is possible that additional types of variants 
will be revealed by analysis of the complete set of variants, 
the analysis to date reveals considerable heterogeneity of the 
phenotypes conferring antibody resistance. Under these se- 
lection conditions, we isolated four major classes of escape 
mutants. These are summarized in Table 1 and described below. 
Mutants of class I are characterized in the greatest detail here. 
Biochemical Characterization fClass I Mutants. The first 
class of mutant was the predominant phenotype after selec- 
tion of 10 s to 10 s HB19 cells with anti-HB19 polyclonal an- 
tiserum from rats immunized with whole borrelias. Not only 
was this type of variant not inhibited by the selecting poly- 
clonal antiserum, it also was resistant to growth inhibition 
by all of the relevant mAbs to OspA and OspB. This resis- 
tance phenotype was unchanged after 20 passages (-v300 
generations) in the absence of antibody. 
Fig. 1 shows the PAGE gel of the wild-type isolate and 
one of the polyclonal antibody-resistant variants, in this case 
R1, before and after protease treatment. The escape variant 
did not have detectable OspA or OspB protein. The absence 
ef Osp proteins in either full-length, truncated, or fused forms 
was confirmed by Western blot analysis with mAbs H5332, 
H3TS, H614, and H68 (data not shown). In place of OspA 
and OspB were an abundant protein of apparent Mr 28,000 
(28K), which seemed to be present in small amounts in the 
wild-type population, and another protein of 36K, which 
was not detectable in the antibody-susceptible population. 
Treatment of the cells with proteinase K provided evidence 
that the 28K and 36K proteins, like Osp and 66K proteins 
(21), are exposed at the cell's surface. 
Mutants lacking OspA and OspB were also selected from 
newly cloned populations of HB19 with the OspB-specific 
mAb H614 or the OspA-specific antibody H5332 in broth 
or solid medium. Using the latter antibody and also the OspB- 
specific mAb H6831, which binds to B31 but not HB19, we 
selected a mutant lacking OspA and OspB from strain B31. 
mAbs to the R1 type of HB19 mutant were produced by 
immunizing mice with viable whole cells; both were IgG3. 
One of the mAbs, 1C8, bound in Western blots to the 28K 
protein of R1 and also to a smaller amount of the protein 
Table 1. Classes of Antibody-resistant Mutants of B. burgdorferi 
Antibody resistance Western blot reactivity 
PAGE Selecting Plus other Selecting Plus other 
Class phenotype antibody antibodies antibody antibodies 
I OspA-OspB-  + 
II AOspA/AOspB* + 
III OspA+OspB + + 
IV OspA § OspB § + 
+ - -  _ 
- -  D + 
- -  + + 
* Truncation of OspA and/or OspB. 
in the population of wild-type cells of HB19 (Fig. 2). mAb 
6B5 was specific forthe 36K of the Osp less-resistant variant. 
This latter mAb did not detectably bind to any protein in 
the wild-type cells (Fig. 2). 
Antibodies 1C8 and 6B5 were used in twofold dilutions 
in the growth inhibition assay in the absence of complement 
(21a). Whereas antibodies 1C8 and 6]35 individually inhibited 
the growth of the Osp-less mutant at dilutions up to 1:2,048 
and 1:8,192, respectively, they did not inhibit the growth 
of the wild-type cells at dilutions as low as 1:8. 
The investigations of this group of mutants indicated that 
OspA and OspB are apparently not required for in vitro 
growth and that other proteins may take the place of the 
Osp proteins at the cell surface. Furthermore, antibodies 
specific for the new proteins inhibit mutant but not wild- 
type cells. 
Genetic Characterization of Class I Mutant~ Absence of both 
OspA and OspB could be explained by either failure of ex- 
pression of the Osl~lB operon or loss of the genes. Inasmuch 
as the osp genes are plasmid borne (48), it was also reasonable 
to attribute the phenotype to absence of the entire linear 
plasmid. Although loss of other linear and supercoiled plasmids 
from/~ burgdorferi had been documented (28, 49), sponta- 
neous or provoked loss of the 49-kb plasmid, which encodes 
OspA and OspB, had not been noted previously. Neverthe- 
less, this possibility was first examined by extraction of total 
DNA and performance of plasmid analysis. Fig, 3, EB, shows 
the absence of the 49-kb linear plasmid from two different 
clones of HB19 mutants with the OspA-OspB- phenotype, 
R1 and R2, and the presence of this plasmid in wild-type 
HB19 (W). In other respects the plasmid profiles were the 
same. Southern blot analysis (Fig. 3, SB) with probes for both 
ospA and ospB genes provided evidence that these genes were 
absent from the remaining plasmids of OspA- OspB- vari- 
ants K1 and R2 while still present in the 49-kb plasmid of 
the antibody-susceptible, OspA + OspB + wild type. To de- 
termine whether the osp genes were present on the chromo- 
some, a Southern blot analysis of total DNA, including chro- 
mosomal and plasmid DNA, which had been digested by
restriction enzymes known to cut within the ost~tB operon, 
was carried out. There were no hybridizing bands in the DNA 
from the resistant variants K1 and K2 (Fig. 4). 
Figure 1. Coomassie blue- 
stained protein of wild type (W) 
and resistant mutant R1 of/~ burg- 
dorferi strain HB19. Spirochetes 
were ( + ) or were not ( -)  treated 
with proteinase K (Protease) be- 
fore cell lysis. The asterisks indi- 
cate proteins of 28K and 36K that 
were present in detectably in- 
creased amounts in R1. Molecular 
weight standards (MWS; xl,000) 
were BSA (68), OVA (43), car- 
bonic anhydrase (29), and B-lacto- 
globulin (18). 
Figure 2. Western blot analysis 
of resistant mutant R1 and wild- 
type (IV) cells of/~ burgdorferi 
HB19 with mAbs to the 28K 
(1C8) and 36K (6B5) proteins of 
R1. The molecular weight stan- 
dards, the locations of which are 
shown to the left, are described 
in the legend of Fig. 1. 
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Figure 3. Resistant mutants R1 and R2 lack the 49-kb linear plasmid 
of wild-type (W) R burgdorferi HB19. (Left) Ethidium bromide-stained 
(EB) 0.2% agarose gel ofplasmid-enriched DNA from spirochetes. (Right) 
Southern blot analysis ($B) of dried gel shown on the left; the probe for 
ospA gene was pTtLH43 (51). Arrowheads indicate th  location of the 49-kb 
plasmid in W cells. The locations in the gel of selected high molecular 
weight standards oflinear DNA (MWS; Bethesda Research Laboratories) 
are shown to the left and are in kilobases. 
Plasmid analysis and Southern blot analysis was lso car- 
ried out with four other Osp-less mutants of HB19 and three 
Osp-less mutants of B31, selected with mAbs H5332, H614, 
or H6831. These mutants, like R1 and R2, lacked the 49-kb 
linear plasmid (data notshown). 
Class II Mutants. The second type of escape mutants, 
among B31 as well as HB19 cells, was observed with mAbs 
but not polyclonal antisera. An example of this type of mu- 
tant is shown in Fig. 5. This escape mutant was selected with 
the OspA-specific mAb H5332. Instead of the OspA and OspB 
proteins of the wild-type B31, a single Osp-like protein of 
slightly smaller apparent size is expressed by the escape mu- 
tant. The partial identity of this protein with Osp proteins 
was demonstrated by the binding in Western blots with Osp- 
specific mAbs. Two OspB-specific antibodies, H6831 and 
H614, bound to the new protein in a Western blot. As ex- 
pected, H5332, the antibody used for selection, did not bind 
to the mutant in the blot. Two other mAbs, H3TS and H68, 
Figure 5. An e:~ample of a class 
II mut~/nt ofR burgdo~'eri. A mu- 
tant selected for growth (+) in the 
presence of the OspA-specific 
mAb H5332 was compared with 
the susceptible ( - )  wild-type 
parent B31. (a) Coomassie blue- 
stained protein of the mutant and 
wild type; the molecular weight 
standards are described in l gend 
for Fig. 1. (b) Western blot anal- 
ysis results with mAbs to different 
epitopes of OspA (H5332 and 
H3TS) and OspB (H6831, H614, 
and H68). 
which were not used for selection, also did not bind to the 
mutant in the blot. H68 binds to an epitope in OspB that 
is distinct from the epitopes recognized by H6831 and H614 
(30). H3TS binds to an OspA that is different from the epi- 
tope bound by H5332 (22). Thus, more than one antibody 
epitope was missing from the mutant cells. These variants 
appeared torepresent truncations and/or fusions of Osp pro- 
teins (54a). 
A similar phenotype of this class were escape mutants of 
HB19 and B31 that by PAGE lacked OspB but still expressed 
full-length OspA proteins (data not shown). These mutants 
were not bound by any of OspB-specific antibody but were 
stiU recognized by both OspA-speciiic mAbs H5332 and H3TS 
in blots. In this respect these variants resembled spontaneous 
OspB- variants observed by Schwan and Burgdorfer and 
Bundoc and Barbour previously (27, 30). 
Class III Mutants. The third type of escape mutant was 
obtained when mAbs were used in either broth or solid media 
but not when polyclonal antisera were used. An e~am_ple of
this class of mutant is shown in Fig. 6. Although the B31 
variant resistant to growth inhibition by antibody H6831 has 
OspA and OspB of the same size as the susceptible wild- 
Figure 4. Southern blot anal- 
)'sis of total DNA from wild-type 
(W) and resistant mutants R1 and 
K2 ofR burgdo~feri HB19. DNA 
was digested with EcoRI and the 
fragments were separated on a 
0.7% agarose gel. After transfer 
to membrane, blots were probed 
for ospB or ospA using pTRH46 
and pTRH43 (51), respectively. 
The locations of mole~lar weight 
standards of 4.0 and 1.2 kb and 
of the 9.5- and 3.0-kb hybridizing 
fragments are shown on the left. The ospA gene but not the adjacent ospB 
gene contains an EcoRI site (52). 
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Figure 6. An example of a class 
III mutant ofR burgdorferi. A mu- 
tam selected for growth (+) in the 
presence of the OspB-specific 
mAb H6831 was compared with 
the susceptible (-) w~d-type parent 
B31. (Left) Coomassie blue- 
stained (CB) proteins of the mu- 
tant and wild type. The migra- 
tions of the OspB proteins, which 
are indicated by arrowheads, of the 
mutant and wild type are iden- 
tical. (Right) Western blot anal- 
)'sis (WB) of gel shown to left; 
the blot was probed with antibody H6831. The molecular weight stan- 
dards are described in the legend for Fig. 1
Table 2. Class III Antibody-resistant Mutants of B. burgdo~Ceri B31 
Western blot analysis 
Selection H5332 6A4B H3TS H614 H6831 H68 
None + + + + + + 
H5332 - + + + + + 
6A4B + - + + + + 
H614 + + + - + + 
H6831 + + + + - + 
type, H6831 did not bind to the resistant mutant in a Western 
blot. Similar findings were made with mutants selected with 
other antibodies. That is, OspA and OspB were unchanged 
in apparent size but the selecting antibody did not bind in 
Western blots. However, unlike the situation with class I and 
II mutants, mAbs to other epitopes of OspA or OspB still 
bound to the escape mutants in blots. A summary of B31 
variants that represented this t ird type of resistance is shown 
in Table 2. Mutants resistant to antibodies H5332, 6A4B 
(OspA), H6831, or H614 (OspB) were no longer ecognized 
by the selecting antibody in blots, while battery antibodies 
that were not used for selection still bound to Osp protein 
and inhibited growth. 
We asked whether mutants of this class had changes limited 
to the epitope site, perhaps the result of point mutations, 
and, accordingly, examined by DNA sequence analysis two
of the B31 mutants, A1 and A3. These mutants, both of which 
had been cloned again after selection, were resistant to the 
growth inhibition by the OspA-specific mAbs H5332 or 6A4B, 
but had an OspA of the same apparent size as the wild type 
and was still bound by other OspA-specific antibodies as well 
as OspB-specific antibodies (Table 2). Other relevant mAbs 
still inhibited the growth of the mutants. The ospA genes 
from the antibody-resistant mutants were amplified by PCR 
and the amplified product was directly sequenced. In the case 
of the H5332-resistant mutant, the ospA1 gene had a single 
base change, a tr nsition from G to A, at nucleotide 616 of 
reference 52 (Fig. 7). The effect of this transition would be 
the replacement i  OspA1 of the position 156 glycine, which 
has a small, aliphatic side chain, with an arginine, which has 
a bulky, basic side chain. Themutant resistant to antibody 
6A4B, which is represented by ospA3 and OspA3 in Fig. 7, 
also had a G to A missense mutation, in this case changing 
the glyeine residue at position 219 of OspA to aspartate with 
its acidic side chain. 
Class IV Mutants. Other escape variants of HB19 grew 
in the presence of antiserum to HB19. PAGE and Western 
blot showed that the variant possessed apparently full-length 
OspA and OspB proteins, which were bound by antibodies 
in polyclonal serum and by the battery ofall specific mAbs 
used in the study (data not shown). This type of escape variant 
was also found among the resistant population of HB19 and 
B31 strains selected with OspA-specific mAb H5332 and the 
OspB-specific mAbs H614 and H6831. In these cases the an- 
tibody neither inhibited the growth nor agglutinated the cells 
of the mutant, but in Western blots it still bound to the Osp 
protein against which the selecting antibody was directed. 
All other elevant antibodies w re still effective atinhibiting 
growth and agglutinating the mutants. The selecting anti- 
bodies also still bound to the antibody-resistant borrelias in 
the indirect immunofluorescence assay, for which whole cells 
were dried and fixed on slides (42). 
Frequency of Mutants in Broth Medium. Although the pri- 
mary goal of this study was an evaluation of the phenotypic 
0SPA: 
OSpA: 
OspA1: 
o~pAl: 
0spA3: 
ospA3: 
OspA: 
ospA: 
OspAl: 
OSpAI: 
0SPA3: 
ospA3: 
OSpA: 
ospA: 
OspAl: 
ospAl: 
OspA3: 
ospA3: 
0spA: 
ospA: 
0spAl: 
ospAl: 
OspA3: 
ospA3: 
OspA: 
ospA: 
OspAl: 
ospAl: 
OspA3: 
ospA3: 
150 160 
AspGlyThrArgLeuGluTyrThrGlyI1eLysSerAspG1ySerGlyLysAlaLysGlu 
GACGGAACCAGACTTGAATACACAGGAATTAAAAGCGATGGATCTGGAAAAGCTAAAGAG 
Arg 
A 
170 180 
ValLeuLysGlyTyrValLeuGluGlyThrLeuThrAlaGluLysThrThrLeuValVal 
GTTTTAAAAGGCTATGTTCTTGAAGGAACTCTAACTGCTGAAAAAACAACATTGGTGGTT 
190 200 
LysGluGlyThrValTbrLeuSerLysAsnIleSerLysSerGlyGluValSerValGlu 
AAAGAAGGAACTGTTACTTTAAGCAAAA.ATATTTCAAAATCTGGGGAAGTTTCAGTTGAA 
210 220 
LeuAsnAspThrAspSerSerAlaAlaThrLysLysThrAlaAlaTrpAsnSerGlyThr 
CTTAATGACACTGACAGTAGTGCTGCTACTAAAAAAACTGCAGCTTGGAATTCAGGCACT 
Asp 
A 
230 240 
SerThrLeuThrIleThrValAsnSerLysLysThrLysAspLeuValPheThrLysGlu 
TCAACTTTAACAATTACTGTAAACAGTAAAAAAACTAAAGACCTTGTGTTTACA.KAAGAA 
Figure 7. Nucleotide and deduced amino acid sequences of two class 
III mutants of a/mrgdo~rer/B31. The osp operons of both mutants were 
sequenced and compared with the sequence of Be~gstr/Sm et al. (52) for 
wild-type osp genes for this strain. Sequences corresponding to amino acids 
140-240 of unprocessed OspA are shown. OspA and os/~l represent the 
wild-type protein and gene. OspA1/o~ell and OspA3/o~U arc the deduced 
protein/nucleotide sequences of mutants resistant to OspA-specific mAbs 
H5332 and 6A4B, respectively. 
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Table 3. Frequency of Mutants Resistant to Selected mAbs among Two Populations of B. burgdo~eri in Broth Medium 
HB19 B31 
Estimated cells 
per well at to H10022 H614 H10022 H5332 H614 
1 
lO 
103 
103 
10 4 
103 
lO 6 
22/48* 0/48 28/48 
(0.6) s (0.9) 
96/96 14/96 96/96 
(3 x 10 -2) 
- 43/48 - 
(4 x 10 -2) 
-r 
0/48  
16/96 
(2 x 10 -4) 
47/48 
(5 x 10 -4) 
0/48 
4/96 
(0.5 x 10 -4) 
* Wells with growth/total wells inoculated per microtiter plate. 
* Not done. 
$ Frequency of cells with growth potential at to. 
diversity of the antibody-resistant mutants, we also estimated 
the frequency of antibody-resistant mutants in populations 
with selected antibodies. For this series of experiments we 
again started with tube cultures, in this case inoculating tubes 
in triplicate or quadruplicate with 101 to 107 spirochetes per 
tube instead of the 10 s we had used in the initial selections. 
Incubation was continued for 14-21 d. If growth was de- 
tected in at least one of the three to four tubes containing 
a given inoculum of cells, the prevalence of variants in the 
original population was estimated to be the reciprocal of that 
inoculum. With strain B31 and mAbs H5332, H6831, or 
H614, resistant mutants were found in at least one of the 
tubes containing 104 borrelias; with >110 s cells per tube, all 
tubes howed growth. This provided an estimate of the prev- 
alence or the frequency of resistant mutants in the B31 popu- 
lation of 10-4 for each of the mAbs. The prevalence of es- 
cape variants among HB19 cells was 10-2 for both H5332 
and H614, but 10-s with polyclonal antiserum to HB19. In 
another experiment in which dilutions calculated to yield an 
average of one HB19 cell per tube were used, 7 of 10 tubes 
without antibody and 1 of 20 tubes with H614 showed growth 
after 14 d of incubation. 
The prevalence ofantibody escape mutants among HB19 
and B31 populations was estimated more precisely using mul- 
tiple samples of the populations (Table 3). Cultures were seri- 
ally diluted in fresh medium and placed as 200-#1 volumes 
in each of 48-96 individual microtiter plate wells; ascitic fluids 
were added for 1:100 dilutions. Antibody H10022, which 
is directed at a surface protein of/~ hermsii, was the control. 
Growth in the wells was followed by observation of change 
in the indicator from pink to yellow and by phase contrast 
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microscopy. If wells showed growth, the culture medium was 
transferred totubes of medium containing the selecting anti- 
body. After growth in the tubes the phenotype ofthe resis- 
tant mutant was examined by PAGE, Western blot, and 
plasmid analysis. The HB19 and B31 populations had been 
cloned again by single-colony plating or limiting dilution 
of these xperiments. The prevalence or frequency of resis- 
tant mutants, i.e., the number of noninhibited cells per well 
at the time of inoculation, was calculated using tables for 
the Poisson distribution. 
Table 3 shows that the frequency of H614-resistant mu- 
tants was again approximately two orders of magnitude higher 
with HB19 cells than with B31 cells. The 14 of 96 wells with 
growth were passed and characterized asto phenotype by 
PAGE, Western blot, and plasmid analysis. Each of the resis- 
tant populations had the dass I phenotype; all lacked the 49-kb 
linear plasmid. The frequency of antibody-resistant mutants 
among B31 population was 2-5 x 10 -4 for antibody 
H5332 and 0.5 x 10 .4 for antibody H614 (Table 3). This 
was similar to what had been observed with tube cultures. 
When the phenotypes ofthe mutants was evaluated we found 
that of the 16 H5332 escape mutants, 1was class I and 15 
were class IV. The 4 H614-resistant mutants were class III. 
Frequency of Mutants on Solid Medium. Current procedures 
for cultivation of/t burgdorferi in solid medium plates yield 
efficiencies of plating between 50 and 100% (42a). There- 
fore, colony growth in the presence of antibodies was more 
likely to represent antibody resistance and not factors leading 
to improved growth on solid medium. Furthermore, in the 
process of cloning individual variant populations and in pre- 
liminary studies of selecting mutants on solid medium, we 
had observed that mutants representing each phenotype class 
grew in solid medium conditions. Thus, solid medium was 
suitable for providing another estimate of variant frequency. 
For this study we used the same newly cloned B31 popu- 
lation of the previous experiment. Antibody H614 was added 
to the top agar of the medium for a concentration 10 times 
the minimum inhibitory level. In studies with broth medium 
we had demonstrated that addition to the medium of 12% 
(vol/vol) ascitic fluid containing an irrelevant mAb did not 
inhibit borrelial growth. To control for the possibility of 
greater sensitivity of colony growth to ascitic fluid in general, 
we included an ascitic fluid control, H10022, in this study 
as well as the no antibody control. The results of colony se- 
lection for resistance to antibody H614 at various inocula of 
B31 cells per plate are shown in Table 4. In this experiment 
the efficiency of plating was between 50 and 100% in plates 
with either no antibody or the irrelevant ascitic fluid. There 
as no difference between efficiency of plating between the 
two controls. On the plates containing the anti-R burgdor- 
fen' antibody, well-demarcated colonies were observed within 
the same time interval that colonies were noted on control 
plates. The colonies growing on the antibody plates had mor- 
phologies that were similar to colonies on control plates. Colo- 
nies were detected on H614 antibody plates at estimated cell 
inocula of 5,000 or greater. The frequency of resistance to 
H614 in B31 on solid medium was estimated to be 0.8-2.9 
x 10 -4, a value similar to the results using broth medium. 
When the phenotypes of the 18 colonies of B31 growing 
on plates containing H614 were determined, 5 were found 
to be class II and 13 were class III. 
Discussion 
The exact mechanism by which antibodies alone inhibit 
the growth of the borrelias is not yet known (21a). Whatever 
Table 4. Frequency of Antibody-resistant Mutants in a 
B. burgdo~feri B31 Population Plated on Solid Medium 
Mean no. colonies/plate* 
Estimate of cells/plate None H10122 H614 
101 6 4 0 
5 x 101 28 40 0 
103 72 91 0 
5 x 103 250 185 0 
103 tntc* tntc 0 
5 x 103 tntc tntc 1 
104 tntc tntc 3 
5 x 104 tntc tntc 8 
10 s tntc tntc 10 
5 x 10 s tntc tntc 40 
" In triplicate. 
* Too numerous to count. 
the mechanism, R burgdo~feri had a variety of ways to escape 
this inhibition under the exper imental  conditions of this study. 
Ultimately, the significance of each of these strategies for 
human and domestic animal disease will need to be evaluated 
in vivo. Evidence to date suggests that antigenic variation 
occurs during the course of R burgdooferi infection in both 
animals and humans, but the phenotypes of the putative vari- 
ants have not been characterized (reviewed in reference 55). 
For further studies of this phenomenon, the present study 
provides an elementary "playbook" with which to analyze 
the hide and seek between the pathogen and the host's im- 
mune system. It may prove easier to follow the action in vivo 
when the strategies are known ahead of time. 
After our first experiments we were stuck by the analogy 
between use of antibodies to achieve growth inhibition and 
use of antibiotics for the same aim. Knowing the value of 
antibiotic-resistant mutants for understanding a number of 
different cdlular functions, we wondered whether antibodies 
could be used to isolate mutants in the surface antigens of 
the borrelias. The methodologies for undertaking enetic 
studies of borrdias are limited, but certainly one that had 
not been utilized to any great extent was the isolation of mu- 
tants in traits of interest (46). 
We have applied the terms "mutation" and "mutant" to 
the phenomena described here. In the case of two classes, 
I and III, an actual change in the genome was documented. 
It is likely that the variants grouped in classes II and IV also 
represent actual change in the DNA. Evidence for this asser- 
tion was the stability of the resistance phenotypes during pas- 
sage in absence of selecting agent. Furthermore, the experi- 
ments with populations divided into small samples in 
microtiter plates indicated that the resistant cells were present 
before exposure to the inhibiting antibody. Only a fraction 
of the wells at certain inocuh showed growth of resistant 
forms. If resistance was an adaptation in response to anti- 
bodies, then one would expect o see growth in each of the 
wells (56). 
Strictly speaking, we can at this point only say that the 
observed changes in the protein components or in the ge- 
nome itsdfwere associated with antibody resistance. To prove 
the cause-and-effect relationship between the altered DNA 
and antibody resistance, the candidate mutation would have 
to be successfully transferred as a well-defined DNA packet 
to an antibody-susceptible/g burgdorferi, thereby conferring 
antibody resistance. As transformation or transduction is not 
yet possible with borrelias, the relationships will remain as- 
sociations by precise definition. Nevertheless, the changes we 
observed in the Osp proteins and the osp genes themsdves 
after selection with mAbs were, in their specificities for the 
selecting antibody, compelling evidence for cause-and-effect 
relationships. 
In terms of attribution, the least ambiguous group of resis- 
tant mutants were those lacking both OspA or OspB pro- 
teins and so placed in class I. All mutants with this pheno- 
type, whether of HB19 or B31 origin, did not have the 49-kb 
plasmid that bears the osp operon. Moreover, there was no 
evidence that this operon had transposed elsewhere in the 
genome. Variants not expressing OspB had been observed 
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previously, but there had not been detectable change in the 
49-kb plasmid or even in the osp genes themselves (27, 28, 
30). There have been strains, such as FI from Sweden and 
DN27 from California, of/~ burgdorferi that did not express 
either the OspA or OspB protein, but in both isolates the 
large plasmids bearing the osp genes were still present (49). 
In addition, both FI and DN27 retain the potential to pro- 
duce OspA (25, 29; A. G. Barbour and S. Bergstr6m, un- 
published observations). 
While the OspA- OspB - mutants of this study have lost 
this potential, the HB19 and B31 lineages examined here did 
express one or two different surface proteins that were ap- 
proximately equivalent toOspA and OspB in abundance. One 
of these proteins, with an apparent size of 28K, was present 
in small amount in the wild-type population. The other pro- 
tein, one of 36K apparent size, was not detectable in the same 
wild-type population by Western blot analysis with specific 
antibody, mAbs with specificities for these new proteins with 
surface xposure inhibited the growth of the OspA-OspB- 
mutants but not the growth of the wild type. These findings 
suggest hat when the 49-kb plasmid is absent, expression 
of other Osp-like genes are derepressed or otherwise upregu- 
lated. This may also occur when the osp operon is still present 
but not expressed. Strains DN27 or FI produce aprotein of 
,x,20-22K when there is no apparent expression of the OSlO 
operon (22, 25, 29, 49). 
OspA-OspB- mutants were first obtained with poly- 
clonal antisera. The rat antiserum to HB19 contained anti- 
bodies to a variety of other proteins besides OspA and OspB 
(21a). Although the studies with mAbs showed that anti- 
bodies to OspA or OspB are sufficient o inhibit growth, 
it is possible that the polyclonal antiserum contained anti- 
bodies to other, less abundant components encoded by the 
49-kb plasmid, and that these antibodies, alone or in con- 
cert, also inhibit borrelial growth. 
Single mAbs to OspA or OspB were also effective for 
selecting OspA-OspB- mutants from a newly cloned popu- 
lation of HB19. The frequency of mutants with this pheno- 
type was "o10 -2 with mAb H614 (Table 3). The frequency 
of OspA-OspB- mutants in the B31 population was 100- 
fold lower. A previous tudy had shown that in B31 the 49-kb 
plasmid is very stable; it was the only linear plasmid left after 
*7,000 generations of in vitro cultivation, and attempts o 
cure the cell of plasmids with agents pecific for DNA or 
its replication (42a). In the present study the plasmid was 
cured using antibody selection. The 49-kb plasmid and the 
Osp proteins it encodes are dispensable for in vitro growth 
in both HB19 and B31. 
The next characterized class of antibody resistance mutants 
was III. The frequency of class III mutations was "o10 -4 in 
B31 and HB19 populations. The examples of this class made 
what appeared to be full-length OspA and OspB proteins, 
and the selecting antibody alone, among the battery's anti- 
bodies, did not bind to the mutant in Western blots. The 
findings uggested that the putative changes in the Osp pro- 
tein were limited to the epitope for the selecting antibody. 
In the two mutants examined in detail for this study, the 
missense mutations, G to A transitions, result in the replace- 
ment of a glycine residue with a charged amino acid. The 
two mutations were in different parts of the OspA sequence, 
as would be expected for the different epitopes for the two 
mAbs (Comstock, et al., manuscript submitted for publica- 
tion). The amino acid change in the H5332-resistant mutant 
occurred in a 13-residue r gion of B31's OspA that differs 
by one and two amino acids from the deduced OspA pro- 
teins of isolates ACAI and Ip90 from Sweden and Russia, 
respectively (26). H5332 inhibits the in vitro growth of B31 
but not ACAI or Ip90 (21a; and unpublished findings). 
The phenotype ofsome class II mutants, for example the 
mutant of Fig. 5, is that of a single chimeric OspA/B pro- 
tein. We have observed spontaneously arising variants of 
B, burgdo[feri inwhich deletion of part of the osp locus generates 
ost~l/B gene fusions that encode a single OspA/B protein 
(54a). Such deletions could be the consequence of homolo- 
gous recombination between ospA and ospB, which share di- 
rect repeats (52). The extent to which the fusion protein an- 
tigenically resembles OspA or OspB reflects the crossover 
point along the genes. Class II mutants that appear to com- 
pletely lack OspB but express full-length OspA may repre- 
sent fusion in which the crossover occurred between the ex- 
treme 3' regions of OSlZ/t and ospB. Alternatively, they could 
have point mutations inospB that prematurely terminate he 
protein, thereby producing the OspB- phenotype. We have 
also observed this type of variant (54a). 
The least understood class of mutants was IV. These mu- 
tants, while no longer inhibited in their growth or aggluti- 
nated by the sdecting antibody, were stiU recognized by the 
antibody by Western blot and an immunofluorescence assay 
using dried, fixed cells. This phenomenon is similar to what 
was observed among antigenic variants of Newcastle disease 
virus; some virus variants, while still capable of binding the 
sdecting antibody in solid phase assays, were only slightly 
neutralized by it (11). These characteristics suggest hat in 
mutants of this class the linear epitope for the antibody is 
not substantially altered but access of the antibody to the 
epitope has been hindered, at least when the proteins are in 
situ and in a native state. If a class IV mutant has a missense 
mutation, it is not likely to be in that part of the gene corre- 
sponding to the linear epitope. The mutation could also be 
in a protein closely associated with the Osp protein target 
in the cell. The effect of the latter type of mutation would 
be to alter or reduce xposure of the epitope. Whatever the 
mechanism, this phenomenon would be unrecognized without 
a function-oriented assay, such as the growth inhibition or 
agglutination. A patient or experimentally infected animal 
may have antibodies that bind in an immunofluorescence or 
Western blot assay but not to viable cells. Such antiboaies 
may make little contribution toan effective immune response. 
The findings encourage further investigation and use of 
the antibody-resistant mutants. The class I mutants lacking 
the genes for OspA and OspB can be used to study the role 
of the proteins in pathogenesis. Such plasmid-less mutants 
could also serve as appropriate hosts for genetic transfer ex- 
periments. In many cases class II mutants appear to be the 
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result of deletions between direct repeats in the osp operon 
(54a). The role of this type of mutation in avoiding the im- 
mune response could be evaluated irectly by applying the 
PCR assay to blood and tissue samples from experimentally 
infected animals and Lyme disease patients. Class III muta- 
tions will be useful for identifying the linear epitopes of mAbs 
against Osp and other proteins that elicit growth-inhibiting 
antibodies. Finally, class IV mutations, while poorly under- 
stood at present, may prove useful for study of the confor- 
mation of Osp proteins in the cell and their interactions with 
other cell components. 
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